A thorough description of cardiovascular events that might be noted with tyrosine kinase inhibitors would include a discussion of the pulmonary arterial hypertension but this focused review was intentionally limited to the most common cardiac events, including systemic hypertension, left ventricular dysfunction, and QT prolongation.